DNAPrint genomics Acquires 18% Stake in German Company Creates New Product Pipeline for Pharmaceutical Products SARASOTA, Fla., July 13 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. (OTC:DNAG) (BULLETIN BOARD: DNAG) today announced that it has acquired an 18% stake in Biofrontera AG of Leverkusen, Germany, for 1.5 million euros. In connection with the transaction, two DNAPrint executives, Richard Gabriel and Hector Gomez, remained on the Biofrontera Board of Directors. "Our relationship with Biofrontera will result in a new pharmaceutical pipeline for DNAPrint genomics," stated Mr. Gabriel, the Company's President and Chief Executive Officer. "Biofrontera already is in Phase II clinical trials with its BF-Derm1 lead product, an anti-itch compound for chronic Urticaria, known as chronic itching and welts brought on by exposure to cold or other allergens that cause a severe skin immune response. It also has a Phase II clinical trial compound for pre-cancerous skin lesions or actinic keratosis known as 5-aminolevulonic acid. Additionally, Biofrontera has advanced a novel prophylactic migraine treatment to pre-clinical development, as well as a series of other compounds at the pre-clinical stage." Hector J. Gomez, M.D., Ph.D., DNAPrint's Chairman and Chief Medical Officer, said the Biofrontera investment is in line with the Company's corporate strategy to leverage its expertise in DNA technology in the development of pharmaceuticals. "We already have one drug in our product pipeline and have begun pre-clinical work with Harvard Medical School's Beth Israel Deaconess Medical Center on PT-401, or Super EPO, a more potent compound for the anemia drug erythropoietin (EPO)," Dr. Gomez said. "The key goal of our pharmaceutical research is the development of test/drug combinations for helping to ensure efficacy with compatible patients." DNAPrint genomics also is continuing to expand its line of forensic products for the law enforcement market and family ancestry products for individual consumers. "We believe the acquisition of Biofrontera AG shares and our presence on the Board of Directors will enable both companies to enhance their abilities to develop products and services and to market and sell their products," Mr. Gabriel noted. "Over the next several months we plan to expand our relationship with Biofrontera, especially in the drug development arena, and we plan to take advantage of each others' locations to help promote our respective products and services in each others' markets." About DNAPrint genomics, Inc. DNAPrint genomics, Inc. ( http://www.dnaprint.com/ ) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (test/drug combination) is PT- 401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre- clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. Forward-Looking Statements All statements in this press release that are not historical are forward- looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Company Contact: Richard Gabriel CEO and President 941-366-3400 -or- Ron Stabiner The Wall Street Group, Inc. 212-888-4848 DATASOURCE: DNAPrint genomics CONTACT: Richard Gabriel, CEO and President, DNAPrint genomics, +1-941-366-3400; or Ron Stabiner, The Wall Street Group, Inc., +1-212-888-4848, for DNAPrint genomics Web site: http://www.dnaprint.com/

Copyright